Background: People who use drugs (PWUD) have high rates of hepatitis C virus (HCV) infection. Hospitalization can be a time for PWUD to engage in addiction treatment, but little is known about how hospitalization shapes HCV treatment readiness. We aimed to describe how hospitalization and addiction medicine consult service (AMCS) can alter HCV prioritization of inpatient PWUD with HCV. Methods: We conducted a qualitative study consisting of semi-structured interviews (n = 27) of hospitalized adults with addiction and HCV infection seen by an AMCS at a single, urban, academic center. Interviews were audio-recorded, transcribed, and coded iteratively at the semantic level, and analyzed for themes. Results: Of the 27 participants, most identified as Caucasian (85%), male gender (67%), and they primarily used opioids (78%); approximately half (48%) reported HCV diagnosis over 5 years ago. We identified three main themes around hospitalization altering the prioritizations and HCV treatment preferences for PWUD: (1) HCV treatment non-engaged (2) HCV treatment urgency, and (3) HCV treatment in the future. Those wanting to treat HCV—whether urgently or in the future—shared the overlapping theme of hospitalization as a reachable moment for their addiction and HCV. These participants recognized the long-term benefits of addressing HCV and connected their hospitalization to substance use. Conclusion: In our study, PWUD with HCV expressed varying and competing priorities and life circumstances contributing to three main HCV treatment trajectories. Our results suggest ways hospitalization can serve as an HCV touchpoint for PWUD, especially in the context of addressing substance use, and could be used when designing and implementing targeted interventions to improve the HCV care continuum for PWUD.
CseteJ, KamarulzamanA, KazatchkineMPublic health and international drug policy. Lancet. 2016;387(10026):1427–1480.
2.
WilliamsIT, BellBP, KuhnertW, AlterMJ.Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med. 2011;171(3):242–248.
3.
ZibbellJE, AsherAK, PatelRCIncreases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175–181.
4.
Centers for Disease Control and Prevention.Viral Hepatitis Surveillance United States, 2017. Atlanta, GA: CDC; 2019:1–63.
Falade-NwuliaO, Suarez-CuervoC, NelsonDR, FriedMW, SegalJB, SulkowskiMS.Oral direct-acting agent therapy for hepatitis c virus infection: a systematic review. Ann Intern Med. 2017;166(9):637–648.
7.
PitcherAB, BorquezA, SkaathunB, MartinNK.Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: a review of the literature and insights for elimination strategies. J Theor Biol. 2019;481:194–201.
8.
HajarizadehB, GrebelyJ, MartinelloM, MatthewsGV, LloydAR, DoreGJ.Hepatitis C treatment as prevention: evidence, feasibility, and challenges. Lancet Gastroenterol Hepatol. 2016;1(4):317–327.
9.
IversenJ, DoreGJ, CatlettB, CunninghamP, GrebelyJ, MaherL.Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. J Hepatol. 2019;70(1):33–39.
10.
KleinMB.Hepatitis C virus elimination: time for disruptive innovation. J Int AIDS Soc. 2019;22(7):1–3.
RosenbergES, HallEW, SullivanPSEstimation of state-level prevalence of hepatitis C virus infection, US states and District of Columbia, 2010. Clin Infect Dis. 2017;64(11):1573–1581.
HøjSB, JackaB, MinoyanN, ArtenieAA, BruneauJ.Conceptualising access in the direct-acting antiviral era: an integrated framework to inform research and practice in HCV care for people who inject drugs. Int J Drug Policy. 2019;72:11–23.
16.
YehiaBR, SchranzAJ, UmscheidCA, Lo ReV.The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014;9(7):e101554–9.
17.
IversenJ, GrebelyJ, CatlettB, CunninghamP, DoreGJ, MaherL.Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. Int J Drug Policy. 2017;47:77–85.
18.
GrebelyJ, BruneauJ, BruggmannPElimination of hepatitis C virus infection among PWID: the beginning of a new era of interferon-free DAA therapy. Int J Drug Policy. 2017;47:26–33.
19.
BaruaS, GreenwaldR, GrebelyJ, DoreGJ, SwanT, TaylorLE.Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163(3):215–223.
20.
HigashiRT, JainMK, QuirkLPatient and provider-level barriers to hepatitis C screening and linkage to care: a mixed-methods evaluation. J Viral Hepat. 2020;27(7):680–610.
21.
LarochelleMR, BernsteinR, BernsonDTouchpoints – opportunities to predict and prevent opioid overdose: a cohort study. Drug Alcohol Depend. 2019;204:1–9.
22.
EnglanderH, WeimerM, SolotaroffRPlanning and designing the improving addiction care team (IMPACT) for hospitalized adults with substance use disorder. J Hosp Med. 2017;12(5):339–342.
23.
WinkelmanTNA, AdmonLK, JenningsL, ShippeeND, RichardsonCR, BartG.Evaluation of Amphetamine-Related Hospitalizations and Associated Clinical Outcomes and Costs in the United States. JAMA Netw Open. 2018;1(6):e183758–13.
RonanMV, HerzigSJ.Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002-12. Health Aff (Millwood)). 2016;35(5):832–837.
26.
EnglanderH, PriestKC, SnyderH, MartinM, CalcaterraS, GreggJ. A call to action: hospitalists’ role in addressing substance use disorder. J Hosp Med. 2019;14(3):E1–E4.
27.
PriestKC, EnglanderH, MccartyD.“Now hospital leaders are paying attention”: a qualitative study of internal and external factors influencing addiction consult services. J Subst Abuse Treat. 2020;110:59–65.
28.
BerkJ, RogersKM, WilsonDJ, ThakrarA, FeldmanL.Missed opportunities for treatment of opioid use disorder in the hospital setting: updating an outdated policy. J Hosp Med. 2020;15(10):619–613.
29.
WakemanSE, MetlayJP, ChangY, HermanGE, RigottiNA.Inpatient addiction consultation for hospitalized patients increases post-discharge abstinence and reduces addiction severity. J Gen Intern Med. 2017;32(8):909–916.
30.
EnglanderH, DobbertinK, LindBKInpatient addiction medicine consultation and post-hospital substance use disorder treatment engagement: a propensity-matched analysis. J Gen Intern Med. 2019;34(12):2796–2803.
31.
TongA, SainsburyP, CraigJ.Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357.
32.
EnglanderH, MahoneyS, BrandtKTools to support hospital-based addiction care: core components, values, and activities of the improving addiction care team. J Addict Med. 2019;13(2):85–89.
33.
GreenJ, ThorogoodN.Qualitative Methods for Health Research. Los Angeles: SAGE; 2004.
34.
AspinallEJ, CorsonS, DoyleJSTreatment of hepatitis c virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57(suppl_2):S80–S9.
35.
AASLD-IDSA. Key populations: identification and management of HCV in people who inject drugs. Recommendations for testing, managing, and treating hepatitis C. https://www.hcvguidelines.org/unique-populations/pwid. Accessed June 6, 2020.
36.
NortonBL, FlemingJ, BachhuberMAHigh HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy. 2017;47:196–201.
37.
WolfeD, LuhmannN, HarrisMHuman rights and access to hepatitis C treatment for people who inject drugs. Int J Drug Policy. 2015;26(11):1072–1080.
38.
PericàsJM, BrombergDJ, OcampoDHepatitis C services at harm reduction centres in the European Union: a 28-country survey. Harm Reduct J. 2019;16(1):20–10.
39.
KikvidzeT, LuhmannN, AvrilEHarm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia. Int J Drug Policy. 2018;52:16–19.
40.
FokuoJK, MassonCL, AndersonARecommendations for implementing hepatitis C virus care in homeless shelters: the stakeholder perspective. Hepatol Commun. 2020;4(5):646–656.
41.
SeamanA, WitkowskaM, ChanB, NelsonL, KorthuisPT.A Novel Hepatitis C Mirco-Elimination Model in a Large Healthcare for the Homeless Organization. Montreal, Canada: International Network on Hepatitis in Substance Users (INHSU); 2019.
42.
KorthuisPT, EdelmanEJ.Substance use and the HIV care continuum: important advances. Addict Sci Clin Pract. 2018;13(1):13.
43.
WilliamsE B, NelonsD, SeamanALife projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs. Int J Drug Policy. 2019;72:138–145.
44.
BatchelderAW, PeyserD, NahviS, ArnstenJH, LitwinAH.“Hepatitis C treatment turned me around:” Psychological and behavioral transformation related to hepatitis C treatment. Drug Alcohol Depend. 2015;153:66–71.
45.
RichmondJA, EllardJ, WallaceJAchieving a hepatitis C cure: a qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in Australia. Hepatol Med Policy. 2018;3(1):1–9.
46.
VegaTA, LevanderXA, SeamanA, KorthuisPT, EnglanderH.“Sobriety equals getting rid of hepatitis C”: a qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults. J Subst Abuse Treat. 2021;127:108337.
47.
MidgardH, FinbråtenAK, MalmeKBOpportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs. Trials. 2020;21(1):1–17.
48.
JonesCD, VuMB, O'DonnellCMA failure to communicate: a qualitative exploration of care coordination between hospitalists and primary care providers around patient hospitalizations. J Gen Intern Med. 2015;30(4):417–424.
49.
MunchhofA, GruberR, LaneKA, BoN, RattrayNA.Beyond discharge summaries: communication preferences in care transitions between hospitalists and primary care providers using electronic medical records. J Gen Intern Med. 2020;35(6):1789–1796.
50.
KattakuzhyS, GrossC, EmmanuelB,et al. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med. 2017;167(5):311–318.
51.
FadnesLT, AasCF, VoldJHIntegrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). BMC Infect Dis. 2019;19(1):1–9.
52.
NealeJ, MillerP, WestR.Reporting quantitative information in qualitative research: guidance for authors and reviewers. Addiction. 2014;109(2):175–176.
KimNJ, LockeCJ, ParkH, MageeC, BacchettiP, KhaliliM.Race and hepatitis C care continuum in an underserved birth cohort. J Gen Intern Med. 2019;34(10):2005–2013.
55.
BruceV, EldredgeJ, LeyvaY, MeraJ, EnglishK, PageK.Hepatitis C virus infection in indigenous populations in the United States and Canada. Epidemiol Rev. 2019;41(1):158–167.
56.
KingC, NicolaidisC, KorthuisPT, PriestKC, EnglanderH.Patterns of substance use before and after hospitalization among patients seen by an inpatient addiction consult service: a latent transition analysis. J Subst Abuse Treat. 2020;118:108121.
57.
King C, Collins D, Patten A, Nicolaidis C, Englander H. Trust in hospital physicians among patients with substance use disorder referred to an addiction consult service: a mixed-methods study. J Addict Med. 2021. doi:10.1097/ADM.0000000000000819. [Epub ahead of print]. PMID: 33577229
58.
SchillieS, WesterC, OsborneM, WesolowskiL, RyersonAB.CDC recommendations for hepatitis C screening among adults – United States. MMWR. 2020;69(2):1–17.
59.
HuttonJ, DoyleJ, ZordanRPoint-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department. Int J Drug Policy. 2019;72:84–90.
60.
LiuL, XuH, HuYHepatitis C screening in hospitals: find the missing patients. Virol J. 2019;16(1):1–9.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
